Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Authors:
- 1 February 2022
- journal article
- review article
- Published by Elsevier in Archives of Medical Research
- Vol. 53 (2) , 186-195
Abstract
No abstract availableKeywords
All Related Versions
This publication has 68 references indexed in Scilit:
- Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reportsDiabetes & Metabolism, 2020
- Role of oxidized LDL-induced “trained macrophages” in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regressionDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Metformin in COVID-19: A possible role beyond diabetesDiabetes Research and Clinical Practice, 2020
- Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering MedicationDiabetes Care, 2020
- COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher’s Stone?Diabetes Therapy, 2020
- Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 DiabetesCell Metabolism, 2020
- Review of Biguanide (Metformin) ToxicityJournal of Intensive Care Medicine, 2018
- Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysisBMJ, 2011